ChemoCentryx, Inc.'s Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit In ANCA-Associated Vasculitis Based On Birmingham Vasculitis Activity Score And Renal Disease Measurements

MOUNTAIN VIEW, Calif., June 2, 2014 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) reported today additional Phase II data related to CCX168, an orally administered inhibitor that targets the receptor for the complement protein known as C5a (C5aR). Data were presented in an oral presentation at the 51st European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, taking place from May 31-June 3 in Amsterdam.

Help employers find you! Check out all the jobs and post your resume.